Novopharm ranitidine will reach market 16 days prior to Zantac expiration; acyclovir generics enter April 23.
NOVOPHARM FORM 1 RANITIDINE WILL REACH U.S. MARKET ON JULY 10, 16 days prior to the expiration of Zantac patent protection, pursuant to a licensing agreement between Novopharm and Glaxo Wellcome announced on April 24. Glaxo Wellcome's form 1 ranitidine patent expires on July 25. The exclusive agreement allows Novopharm to begin manufacturing ranitidine at its Wilson, N.C. plant on June 3, "allowing ample time to produce enough quantities to satisfy the anticipated demand for the product," the generics firm said.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth